BioStock recaps the Breakthrough T1D Mission Summit held in Miami on October 25–27, where leading researchers, clinicians, and industry voices discussed scientific progress and disease-modifying strategies that could change the course of type 1 diabetes.

Anton Lindqvist, Chief Scientific Officer at Diamyd Medical, participated in the summit, contributing to discussions on emerging strategies to preserve insulin production. The discussion centered on preserving endogenous insulin production and accelerating therapies that improve long-term outcomes for people with T1D.

Read the article here